𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Milacemide therapy for Parkinson's disease

✍ Scribed by M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
303 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased overall parkinsonian severity transiently, mostly due to an effect on rigidity. Milacemide did not, however, alter levodopa‐induced dyskinesias. These results support the view that drugs acting on the glutamatergic system can influence motor function in patients with extrapyramidal movement disorders and that pharmaceutical agents that selectively block certain subtypes of glutamate receptors may ameliorate parkinsonian symptoms.

📜 SIMILAR VOLUMES

Neuroprotective Therapy for Parkinson's
Neuroprotective Therapy for Parkinson's disease
✍ I.Shoulson and the Parkinson Study Group 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective th

Gene therapy for Parkinson's disease
Gene therapy for Parkinson's disease
✍ Tomas Bjorklund; Jeffrey H. Kordower 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

## Abstract The once fantastic theoretical concept that patients with Parkinson's disease (PD) would receive gene therapy in an attempt to alleviate their symptoms and potentially modify the course of their disease has become a reality. On the basis of positive preclinical data, four different gene

Mitochondrial therapies for Parkinson's
Mitochondrial therapies for Parkinson's disease
✍ Bobby Thomas; M. Flint Beal 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center sta

Parkinson's disease/Parkinson syndromes—
Parkinson's disease/Parkinson syndromes—therapy: Levodopa
📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

Three patients with Parlcinson's disease, optimally treated with levodopdcabidopa (LDKD) tablets, but experiencing severe motor fluctuations, were administered a solution of levodopd carbidopalascorbic acid (LCAS) orally at intervals ranging from 30 to 60 minutes. Patients were rated half-hourly to

Parkinson's disease/Parkinson syndromes—
Parkinson's disease/Parkinson syndromes—therapy: Clozapine
📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Cabergoline ( C b ) is a U-2 ergot derivative with a long active half-life O 4 8 h ) . In a n open rising dose study we added C b to levodopa+inhibitor in 3 0 parkinsonian patients w i t h motor fluctuations. C h m e a n daily dose w a s 13.3(6-20). given once a day. for a mean period of 1 8 . 3 16-